TP53 and cancer: Since low transduction is a major issue with these approved replication defective AV drugs, more advanced tumor-specific p53-expressing conditionally replicating AV vectors such as ONYX 015, AdDelta24-p53, SG600-p53, H101, and OBP-702 have been developed but none of them is approved for cancer treatment to date.